Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
ARRAY BIOPHARMA RG (NQ: ARRY)
16.98 USD  -0.10 (-0.59%)
Official Closing Price  /  Updated: 8:00 PM EDT, Jul 20, 2018  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 1,098,720
Open 17.12
Bid (Size) 16.88 (400)
Ask (Size) 17.18 (300)
Prev. Close 17.08
Today's Range 16.89 - 17.37
52wk Range 7.150 - 20.20
Shares Outstanding 210,637,094
Dividend Yield N/A
Performance
YTD
+25.31%
+25.31%
1 Month
-15.06%
-15.06%
3 Month
+20.51%
+20.51%
6 Month
+29.22%
+29.22%
1 Year
+102.63%
+102.63%
Top News
More News
The National Comprehensive Cancer Network (NCCN) Guidelines Recommend BRAFTOVI™ (encorafenib) in Combination with MEKTOVI® (binimetinib) as a Category 1 Treatment Option for Patients with Advanced BRA
Array BioPharma Inc. (NASDAQ: ARRY) today announced that the National Comprehensive Cancer Network (NCCN) has updated the Clinical Practice Guidelines in Oncology for Melanoma to include BRAFTOVI™ in... Read More
from PR Newswire
Array BioPharma Announces FDA Approval of BRAFTOVI™ (encorafenib) in Combination with MEKTOVI® (binimetinib)
- Approval based on Phase 3 COLUMBUS trial which demonstrated nearly 15 months median progression-free survival - Read More
from PR Newswire
More News
Read More
Array BioPharma Announces a 62% Observed Overall Survival at One Year from the Phase 3 BEACON CRC Safety Lead-In of the Combination of Encorafenib, Binimetinib and Cetuximab in BRAF-Mutant CRC at the
from PR Newswire
Biotech Resurgent Growth Championed by Cancer Research and Clinical Trial Advancements
from PR Newswire
Analysts See 19% Upside For The Holdings of PTH
category ETFs
from ETF Channel
Bearish Moving Average Cross by Array Biopharma (ARRY)
from Comtex SmarTrend® News Briefs
Piper Jaffray, Stifel Defend Array Biopharma As Stock Falls On Profit-Taking
category General , Analyst Ratings , Price Target , and 15 more.
from Benzinga
UPDATE 2-Array BioPharma gets FDA nod for melanoma combo treatment
category companyNews
from Reuters: Company News
Array BioPharma Touts Approval Of Melanoma Drug
category General , Braftovi , ARRY , and 5 more.
from Benzinga
Biotechnology Stocks Preparing A New Bullish Trend
category Stocks / Equities , Pharma/Biotech
from Blogs - TalkMarkets
CORRECTED-UPDATE 1-FDA approves Array BioPharma's melanoma combo treatment
category companyNews
from Reuters: Company News
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.